AstraZeneca stock rose early Thursday after the drugmaker beat fourth-quarter earnings views and delivered upbeat guidance.

AstraZeneca on Thursday warned that it could be fined millions of dollars in importation tax fines as Chinese authorities ...

Roche has secured a new FDA approval for its first companion diagnostic test aimed at identifying breast cancer patients with ...

The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...

AstraZeneca Plc reported better-than-expected profit and revenue in the fourth quarter and forecast further gains, helped by ...

In addition to the UK investment controversy, AstraZeneca is also dealing with legal challenges in China. The company ...

Earnings per share excluding some items surged to $2.09, Astra said Thursday, higher than the $2.04 estimated by analysts ...

AstraZeneca scrapped plans for a £450 million UK vaccine plant after rejecting a £78 million government offer, citing ...

AstraZeneca Plc (NASDAQ:AZN) reported fourth-quarter sales of $14.89 billion, up 18% year over year (+19% at constant ...

FDA approves Enhertu for metastatic breast cancer with HER2-low or HER2-ultralow expression after showing significant ...

How an agreement set up by the Tories and lauded by Labour fell victim to cost-cutting and UK curbs on drugs expenditure ...

The boss of drugmaker AstraZeneca has said he was “very disappointed” with the firm’s move to scrap plans for a £450 million ...